What's breaking now, across thousands of outlets.
Side effects observed in testing have led Novartis to halt development of rap-cel in multiple indications and Bristol Myers to voluntarily pause its zola-cel program.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
(MedPage Today) -- Use of GLP-1 receptor agonists was associated with increased cumulative gallbladder and biliary events in youths, according to a retrospective analysis of TriNetX data.
A 76-year-old man with prostate cancer has been detained by immigration officials for more than two months, relatives said.
(MedPage Today) -- Recent studies suggest that people with type 2 diabetes on GLP-1 receptor agonists were less likely to develop tuberculosis (TB) or be hospitalized or die from infections.
Kenya has secured a major breakthrough in cancer treatment after signing an agreement with US pharmaceutical giant Pfizer that will significantly reduce the cost of medicines used to treat several…
A new spatial transcriptomics framework compares tumor “floor plans." In a study of 262 solid tumors, the team identified recurring spatial groups that may connect spatial structure, biological…
[This Day] Aspectre of health problems trailed Dolly Parton's larger-than-life public persona. First, she was in her 30s when she was diagnosed with endometriosis, a chronic medical condition where…
